

## Richard W. Dugan Joins Xanthus Life Sciences' Board of Directors

CAMBRIDGE, Mass., Dec. 22 /PRNewswire/ -- Xanthus Life Sciences, Inc., a privately-held oncology drug development company, today announced the election of Richard W. Dugan to the Company's Board of Directors. His appointment increases Xanthus' board to five members, including four non-employee directors.

Mr. Dugan has a distinguished business background, having served as a Partner with Ernst & Young, LLP from 1976 to 2002. While with the firm, Mr. Dugan held a variety of managing and senior partner positions, including Mid-Atlantic Area Senior Partner, Mid-Atlantic Area Managing Partner, and Pittsburgh Office Managing Partner. Mr. Dugan retired from Ernst & Young LLP in September, 2002

"Dick brings to Xanthus significant financial and strategic experience in helping guide businesses to evolve from early-stage development companies to broader, publicly-traded corporate enterprises," stated Richard T. Dean, Ph.D., President and CEO of Xanthus. "Dick's understanding of the unique issues confronting rapidly-evolving biopharmaceutical companies complements the skills and experience of our current board members at this important stage of our corporate development."

Mr. Dugan received a B.S.B.A. from Pennsylvania State University. He currently serves as a Board Member and Chair of the Audit Committee for Advancis Pharmaceutical Corporation (Germantown, MD), and Critical Therapeutics, Inc. (Lexington, MA). Both firms are publicly traded on NASDAQ.

About Xanthus Life Sciences, Inc.

Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical-stage, small-molecule oncology drugs through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise both to advance its current pipeline and expand it into indications of unmet medical need beyond oncology.

Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at <http://www.xanthus.com>.

Contacts:

Kari Watson, MacDougall Biomedical Communications, Inc. -  
[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com) or (508) 647-0209

John A. McCarthy, Jr., Senior Vice President & CFO, Xanthus Life Sciences, Inc. - [john.mccarthy@xanthus.com](mailto:john.mccarthy@xanthus.com) or (617) 225-0522, x 125

SOURCE Xanthus Life Sciences, Inc.

-0-

12/22/2005

/CONTACT: Kari Watson of MacDougall Biomedical Communications, Inc., +1-508-647-0209, kwatson@macbiocom.com; or John A. McCarthy, Jr., Senior Vice President & CFO of Xanthus Life Sciences, Inc., +1-617-225-0522, ext. 125, john.mccarthy@xanthus.com/

/First Call Analyst: /

/FCMN Contact: /

/Web site: <http://www.xanthus.com/>